Diagnostic performance of computed tomography-guided percutaneous bone biopsy in musculoskeletal oncology: A single-center cohort study

Table 4 Availability of final verification and follow-up information

Verification item	What the supplied record supports	What remains unresolved
All included procedures	64 records	Unique patient count, repeat-procedure handling, and all screened/excluded totals (AQ1)
Diagnostic procedures with recorded final assessment	60/64, all reported concordant	Case-level matching of diagnoses, malignancy/subtype/grade rules, adjudicator identity and blinding (AQ2)
Surgical histopathology	Used for some resected lesions	Exact n/64 and n/60, dates, and independence from the index interpretation (AQ2)
IHC-supported oncologic work-up	Reported for the three metastatic categories (10 + 10 + 8) and for some myeloma cases	Exclusive route counts, source specimen, overlap with surgery/follow-up, and category reconciliation (AQ2/AQ4)
Clinical and imaging follow-up	Used in several source categories; six-month minimum stated previously	Actual duration for each case, median/range, final cutoff, number with ≥ 6 months, and losses to follow-up (AQ3)
Non-diagnostic procedures	4/64; no confirmed final diagnosis/follow-up reported	Subsequent outcome and any repeat procedure; do not reclassify as benign or false-negative without evidence
Adverse-event surveillance	Immediate CT assessment; two delayed local fistulas described	Complete surveillance interval and missing follow-up for all 64 (AQ7)
Baseline and procedural variables	Aggregate sex, morphology, anesthesia, guidance categories	Age, lesion size/depth, complete sites, actual cores, treatment exposure, and missingness counts (AQ4-AQ5)

“Not reported” identifies a gap in the supplied summary, not proof that information was never collected. No exclusive reference-standard counts, missingness frequencies, or follow-up durations have been manufactured from the grouped categories. CT: Computed tomography; IHC: Immunohistochemistry.